Company Filing History:
Years Active: 2016-2017
Title: Roy Sirkis - Innovator in Fibroblast Growth Factor Research
Introduction
Roy Sirkis is a distinguished inventor based in Ness Ziona, IL, known for his significant contributions to the field of fibroblast growth factors. With a total of 2 patents to his name, Sirkis has made notable advancements geared towards therapeutic applications, particularly in treating cartilage and skeletal disorders.
Latest Patents
Sirkis's latest patents include:
1. **Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof** - This invention focuses on conjugates formed from hydrophilic carboxy polysaccharides and protein members of the fibroblast growth factor (FGF) family. These conjugates enhance the bioactivity and stability of FGFs, positioning them for various therapeutic uses.
2. **FGF-18 truncated variants having increased receptor specificity and uses thereof** - This patent addresses fibroblast growth factor 18 (FGF-18) variants with truncations beyond the N-terminus signal peptide domain. These variants activate FGFR3 with enhanced specificity, and the invention also includes polynucleotides encoding these variants, pharmaceutical compositions comprising them, and methods for treating cartilage and skeletal disorders.
Career Highlights
Roy Sirkis currently works at Hepacore Ltd, where he collaborates on innovative healthcare solutions. His work primarily involves advancing the applications of fibroblast growth factors, which are crucial in various therapeutic contexts, particularly in orthopedics and regenerative medicine.
Collaborations
Sirkis has collaborated with notable colleagues such as Avner Yayon and Eran Rom. These partnerships have significantly enriched his research and led to meaningful advancements in the understanding and application of FGFs in medical science.
Conclusion
In summary, Roy Sirkis's inventions and research activities represent important strides in biotechnology, particularly in the area of fibroblast growth factors. His innovative approach and collaborative spirit continue to pave the way for therapeutic advancements that hold promise for treating significant health challenges.